Clinical trials: Anti-vascular Endothelial Growth Factor
Age-Related Macular Degeneration
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related…
- Trial name
- NCT05984927
- Testing
- NG101 AAV gene therapy
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Elisigen, Inc.
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Diabetic Macular Edema (DME)
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision.
- Trial name
- NCT07338097
- Testing
- Aflibercept (2.0 mg), Bevacizumab
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- CMH Multan Institute of Medical Sciences
Age Related Macular Degeneration
Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Age Related Macular Degeneration (AMD) is the leading cause of blindness in North America. This condition causes a progressive loss of central vision, the part of your vision that allows you to read, drive and see images in sharp…
- Trial name
- NCT01363570
- Testing
- Ranibizumab
- Where
- 2 sites in Canada
- Volunteers
- 70 people
- Sponsor
- McMaster University
Age-Related Macular Degeneration
The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
Patients are already receiving an intravitreal injection as a standard of care, but they are consenting to receiving a loteprednol drop following the intravitreal injection.
- Trial name
- NCT05542381
- Testing
- Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Virginia Polytechnic Institute and State University
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema, Cataract
Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery
The investigators aim to evaluate how different timing of anti-VEGF intravitreous injections affect visual acuity (BCVA) in patients with diabetic macular edema who are undergoing cataract surgery; and to evaluate how different…
- Trial name
- Anti-VEGF (NCT04063358)
- Testing
- Lucentis
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Military Medical University
Diabetic Macular Edema
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Although multiple studies have suggested that treatment with ranibizumab is safe and efficacious and superior to focal/grid laser alone for patients with center-involved diabetic macular edema (DME), there may be barriers in…
- Trial name
- Protocol T (NCT01627249)
- Testing
- 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
- Where
- 90 sites in United States
- Volunteers
- 660 people
- Sponsor
- Jaeb Center for Health Research
Irvine-Gass Syndrome
Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept
This research study is being conducted to determine the safety and tolerability of subconjunctival injections of aflibercept in the treatment of pseudophakic cystoid macular edema that has not responded well to first-line…
- Trial name
- ACME (NCT03396861)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
Branch Retinal Vein Occlusion
Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion
Retinal vein occlusion (RVO) is the second leading cause of retinal vascular disease in patients older than 50 years.The prevalence varies from 0.7% to 1.6% in the literature.
- Trial name
- NCT02033031
- Testing
- Lucentis intravitreal injection, Avastin intravitreal injection
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Medical University of Vienna
Neovascular Glaucoma, Neovascularization
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension eyedrop in the treatment of neovascular glaucoma.
- Trial name
- KDR-NVG (NCT04844619)
- Testing
- 4mg/ml KDR2-2 suspension eyedrop, 16mg/ml KDR2-2 suspension eyedrop
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Eye Diseases, Injection Complication
Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections
This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth…
- Conditions
- Eye Diseases, Injection Complication, Intraocular Pressure
- Trial name
- NCT04523844
- Testing
- Brinzolamide-brimonidine Fixed Combination
- Where
- Greece
- Volunteers
- 47 people
- Sponsor
- General Hospital of Athens Elpis
Ophthalmology, Macular Degeneration
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31…
- Trial name
- AURA (NCT01447043)
- Testing
- Ranibizumab
- Where
- 10 sites in Australia, Canada and 8 more
- Volunteers
- 2,609 people
- Sponsor
- Bayer
Macular Polypoidal Choroidal Vasculopathy (PCV)
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor…
- Trial name
- PROUD (NCT05666804)
- Testing
- Brolucizumab 6mg
- Where
- 15 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Malignancy
A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies
The well-established role of vascular endothelial growth factor (VEGF) in carcinogenesis and tumor angiogenesis has led to the development of agents that target this pathway.
- Trial name
- NCT00978926
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Endophthalmitis
Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics
This is a prospective case series which aims to determine the incidence of endophthalmitis following intravitreous anti-vascular endothelial growth factor (VEGF) injection comparing between eyes receiving post-injection…
- Trial name
- NCT02810587
- Testing
- Topical antibiotics following injection
- Where
- Thailand
- Volunteers
- 5,000 people
- Sponsor
- Chiang Mai University
Macular Degeneration
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31…
- Trial name
- REVIEW (NCT01933152)
- Testing
- Ranibizumab
- Where
- Portugal
- Volunteers
- 137 people
- Sponsor
- Bayer
Retinopathy of Prematurity
Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical Anesthesia
Purpose: To evaluate the incidence and severity of hypoxia and address a genuine evidence gap focusing on intraprocedural hypoxia during bedside intravitreal ranibizumab injection for retinopathy of prematurity (ROP), an area…
- Trial name
- NCT07701759
- Testing
- ranibizumab
- Where
- Saudi Arabia
- Volunteers
- 74 people
- Sponsor
- Minia University
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or…
- Trial name
- NCT06449209
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- BioNTech SE
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei